A Swiss biotech firm developing a Covid treatment has seen its share price soar 38,000% this year
December 14, 2020 at 02:45 AM EST
Swiss biotech firm Relief Therapeutics has seen its share price climb by nearly 38,000% so far this year, as it develops a drug focused on respiratory failure arising from severe Covid-19.